Concert Pharmaceuticals is a biotechnology business based in the US. Concert Pharmaceuticals shares (CNCE) are listed on the NASDAQ and all prices are listed in US Dollars. Concert Pharmaceuticals employs 64 staff and has a trailing 12-month revenue of around $32 million.
Our top picks for where to buy Concert Pharmaceuticals stock
How to buy Concert Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – CNCE. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Concert Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Concert Pharmaceuticals stock price (NASDAQ: CNCE)
Use our graph to track the performance of CNCE stocks over time.Concert Pharmaceuticals shares at a glance
Latest market close | $8.37 |
---|---|
52-week range | $0.00 - $0.00 |
50-day moving average | $7.68 |
200-day moving average | $6.05 |
Wall St. target price | $13.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-3.17 |
Is it a good time to buy Concert Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Concert Pharmaceuticals price performance over time
Historical closes compared with the close of $8.37 from 2023-03-06
1 week (2024-08-27) | N/A |
---|---|
1 month (2024-08-03) | N/A |
3 months (2024-06-03) | N/A |
6 months (2024-03-03) | N/A |
1 year (2023-09-03) | N/A |
---|---|
2 years (2022-09-07) | 24.93% |
3 years (2021-09-07) | 139.83% |
5 years (2019-09-06) | 11.19 |
Concert Pharmaceuticals financials
Revenue TTM | $32 million |
---|---|
Gross profit TTM | $-54,977,000 |
Return on assets TTM | -38.53% |
Return on equity TTM | -108.68% |
Profit margin | 0% |
Book value | $2.78 |
Market Capitalization | $401.9 million |
TTM: trailing 12 months
Concert Pharmaceuticals share dividends
We're not expecting Concert Pharmaceuticals to pay a dividend over the next 12 months.
Concert Pharmaceuticals share price volatility
Over the last 12 months, Concert Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Concert Pharmaceuticals's is 0.5205. This would suggest that Concert Pharmaceuticals's shares are less volatile than average (for this exchange).
Concert Pharmaceuticals overview
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc. ; Jazz Pharmaceuticals, Inc. ; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Frequently asked questions
nullWhat percentage of Concert Pharmaceuticals is owned by insiders or institutions?
Currently 3.773% of Concert Pharmaceuticals shares are held by insiders and 77.053% by institutions. How many people work for Concert Pharmaceuticals?
Latest data suggests 64 work at Concert Pharmaceuticals. When does the fiscal year end for Concert Pharmaceuticals?
Concert Pharmaceuticals's fiscal year ends in December. Where is Concert Pharmaceuticals based?
Concert Pharmaceuticals's address is: 65 Hayden Avenue, Lexington, MA, United States, 02421 What is Concert Pharmaceuticals's ISIN number?
Concert Pharmaceuticals's international securities identification number is: US2060221056 What is Concert Pharmaceuticals's CUSIP number?
Concert Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 206022105
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question